Perspectives of IMerge Study

Author(s):

Guillermo Garcia-Manero, MD,Rami Komrokji, MD

Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations.

EP: 1.Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification

EP: 2.Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 

EP: 3.Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies

EP: 4.Review of the COMMANDS Trial

EP: 5.Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial

EP: 6.Clinical Implications of COMMANDS Trial in Clinical Practice

EP: 7.Treatment Decision-Making Based on the COMMANDS Trials

EP: 8.Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024

EP: 9.Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

EP: 10.Safety Profile of Available Frontline Treatments LR-MDS

EP: 11.1L treatment of lower-risk MDS beyond luspatercept

EP: 12.Sequencing Second-Line Treatments for LR-MDS

Now Viewing

EP: 13.Perspectives of IMerge Study

EP: 14.Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024

EP: 15.EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates

EP: 16.Final Thoughts on EHA 2024 Data for Lower-Risk MDS

Please comment on which patients you would consider 2L imetelstat for patients with LR-MDS.
1. Please provide a summary of the IMerge study, evaluating imetelstat in patients that R/R to ESAs in LR-MDS. (Platzbecker U, Santini V, Fenaux P, et al. Lancet. 2024;403(10423):249-260.)
2. Dr Komrokji: How does the latest follow up from the IMergestudy support the use of imetelstat in patients with LR-MDS?